摘要
目的观察孟鲁司特在慢性阻塞性肺疾病急性加重期临床治疗中的疗效与安全性。方法选择2012年~2016年间的100例慢性阻塞性肺疾病患者,随机将其分为对照组和观察组,两组均为50例。对照组给予常规抗感染、舒张支气管平滑肌、促进痰液排出和激素类药物治疗,观察组在对照组的基础上给予口服孟鲁司特进行治疗,对比分析两组的临床效果、不良反应发生率以及治疗前后肺功能参数与血气指标。结果观察组临床总有效率明显高于对照组(P<0.05);观察组与对照组均无严重不良反应发生,两组不良反应发生率比较,差异无统计学意义(P>0.05);两组患者治疗前肺功能参数与血气指标对比无明显差异(P>0.05),经治疗后观察组各肺功能参数及血气指标显著优于治疗前(P<0.05),对照组治疗后较治疗前各肺功能参数及血气指标改善程度不明显(P>0.05)。结论在慢性阻塞性肺疾病患者急性加重期治疗中应用孟鲁司特,可有效提高疗效,改善肺功能参数与血气指标,安全性较高,值得推广应用。
Objective To explore the effects and security of montelukast for COPD. Methods 100 cases with COPD from 2012 to 2016 were selectedand divided into control group （n = 50） and observation group （n = 50）. The control group was taken routine nursing and observation group was treatedas montelukast on the basis of the control group. The effects, adverse reactions, pulmonary function parameters and blood-gas parameters in the two groupswere compared. Results The total effective rate in observation group was significant higher than controlgroupThere was no significant difference of adversereactions in the two groups.After treatment, the pulmonary function and blood-gas parameters were superior to before. The improvement of pulmonary functionand blood-gas parameters in control group was not obvious. Conclusion Montelukast can improve the total effective rate, pulmonary function and blood-gasparameters of COPD patients.
作者
李东伟
LI Dong-wei(Department of respiratory medicine,Dagang Hospital of Binhai District,Tianjin 300270,China)
出处
《中国处方药》
2018年第6期71-72,共2页
Journal of China Prescription Drug
